Literature DB >> 17117366

Evaluation of the humoral immune response in BALB/c mice immunized with a naked DNA vaccine anti-methicillin-resistant Staphylococcus aureus.

D M Roth1, J P M Senna, D C Machado.   

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is the major pathogen involved in nosocomial infections, leading to high rates of morbidity and mortality in hospitals worldwide. The methicillin resistance occurs due to the presence of an additional penicillin-binding protein, PBP2a, which has low affinity for beta-lactam antibiotics. In the past few years, vancomycin has been the only antibiotic option for treatment of infections caused by multiresistant MRSA; however, reports of vancomycin-resistant strains have generated great concerns regarding the treatment to overcome these infections. In the present study, we report preliminary results regarding the humoral immune response generated in BALB/c mice by two different doses of naked DNA vaccine containing an internal region, comprising the serine-protease domain, of the PBP2a of MRSA. The immunization procedure consisted of four immunizations given intramuscularly within 15-day intervals. Blood was collect weekly and anti-PBP2a-specific antibodies were screened by ELISA. BALB/c mice immunized with DNA vaccine anti-PBP2a have shown higher antibody titers mainly after the fourth immunization, and intriguingly, no correlation between the humoral immune response and DNA dose was observed. Our results suggest that the DNA vaccine anti-PBP2a induced an immune response by production of specific antibodies anti-MRSA in a non-dose-dependent manner, and it could represent a new and valuable approach to produce specific antibodies for passive immunization to overcome MRSA infections.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17117366

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  6 in total

1.  Recombinant ESAT-6-like proteins provoke protective immune responses against invasive Staphylococcus aureus disease in a murine model.

Authors:  Bao Zhong Zhang; Yan Hong Hua; Bin Yu; Candy Choi Yi Lau; Jian Piao Cai; Song Yue Zheng; Wing Cheong Yam; Richard Yi Tsun Kao; Kong Hung Sze; Bo Jian Zheng; Kwok Yung Yuen; Jian Dong Huang
Journal:  Infect Immun       Date:  2014-11-03       Impact factor: 3.441

Review 2.  DNA vaccines for targeting bacterial infections.

Authors:  Mariana Ingolotti; Omkar Kawalekar; Devon J Shedlock; Karuppiah Muthumani; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2010-07       Impact factor: 5.217

3.  Recombinant PBP2a/autolysin conjugate as PLGA-based nanovaccine induced humoral responses with opsonophagocytosis activity, and protection versus methicillin-resistant Staphylococcus aureus infection.

Authors:  Setareh Haghighat; Seyed Davar Siadat; Abbas Akhavan Sepahi; Mehdi Mahdavi
Journal:  Iran J Basic Med Sci       Date:  2022-04       Impact factor: 2.532

4.  Luteolin potentiates the effects of aminoglycoside and β-lactam antibiotics against methicillin-resistant Staphylococcus aureus in vitro.

Authors:  Dae-Ki Joung; Ok-Hwa Kang; Yun-Soo Seo; Tian Zhou; Young-Seob Lee; Sin-Hee Han; Su-Hyun Mun; Ryong Kong; Ho-Jun Song; Dong-Won Shin; Dong-Yeul Kwon
Journal:  Exp Ther Med       Date:  2016-03-31       Impact factor: 2.447

5.  Immunotherapy Targeting Adenosine Synthase A Decreases Severity of Staphylococcus aureus Infection in Mouse Model.

Authors:  Bao-Zhong Zhang; JianPiao Cai; Bin Yu; Lifeng Xiong; Qiubin Lin; Xiao-Yan Yang; Chen Xu; SongYue Zheng; Richard Yi-Tsun Kao; Konghung Sze; Kwok-Yung Yuen; Jian-Dong Huang
Journal:  J Infect Dis       Date:  2017-07-15       Impact factor: 5.226

6.  Cloning, Expression and Purification of Penicillin Binding Protein2a (PBP2a) from Methicillin Resistant Staphylococcus aureus: A Study on Immunoreactivity in Balb/C Mouse.

Authors:  Setareh Haghighat; Seyed Davar Siadat; Seyed Mehdi Rezayat Sorkhabadi; Abbas Akhavan Sepahi; Mehdi Mahdavi
Journal:  Avicenna J Med Biotechnol       Date:  2013-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.